Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13244846 | 0.93 | SSTR3 (0.44) | SSTR3KCNH2 | |
| SCHEMBL3008099 | 0.85 | SSTR3 (0.45) | SSTR3KCNH2 | |
| SCHEMBL13244879 | 0.80 | KDM4E (0.49) | SSTR3KCNH2 | |
| SCHEMBL13244848 | 0.78 | SSTR3 (0.40) | SSTR3KCNH2 | |
| SCHEMBL3002454 | 0.75 | SSTR3 (0.73) | SSTR3KCNH2 | |
| SCHEMBL13244822 | 0.74 | SSTR3 (0.55) | SSTR3KCNH2 | |
| SCHEMBL13244670 | 0.73 | SSTR3 (0.46) | SSTR3KCNH2 | |
| SCHEMBL3013321 | 0.73 | SSTR3 (0.73) | SSTR3KCNH2 | |
| SCHEMBL3014223 | 0.73 | SSTR3 (0.44) | SSTR3KCNH2 | |
| SCHEMBL13244716 | 0.72 | SSTR3 (0.69) | SSTR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184758-A1 | BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2010-07-22 | — | — | US | disclosed |
| US-20100184758-A1 | BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2010-07-22 | — | — | US | disclosed |
| WO-2009011836-A1 | BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | MERCK & CO., INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184758-A1 | BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | GPR119, SSTR3, SSTR2 | SSTR3 2/4885KCNH2 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.